NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients

CompletedNA

Sponsor: Johns Hopkins University

Conditions: Hiv

Interventions: HIV D+/R+

Countries: United States

The primary objective of this study is to determine if an HIV-infected deceased kidney donor (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participant meets the standard criteria for kidney transplant at the local center.
* Participant is able to understand and provide informed consent.
* Participant meets with an independent advocate per the HIV Organ Policy Equity (HOPE) Act Safeguards.
* Documented HIV infection (by any licensed assay, or documented history of detectable HIV-1 RNA).
* Participant is ≥18 years old.
* Opportunistic complications: if prior history of an opportunistic infection, the participant has received appropriate therapy and has no evidence of active disease.
* Cluster of Differentiation 4 (CD4)+ T-cell: ≥200/µL within 16 weeks of transplant.
* HIV-1 is below 50 copies RNA/mL. Viral blips between 50-400 copies allowed as long as there are not consecutive measurements \>200 copies/mL.
* Participant is willing to comply with all medication related to their transplant and HIV management.
* For participant with a history of aspergillus colonization or disease, no evidence of active disease.
* The participant must have, or be willing to start seeing, a primary medical care provider with expertise in HIV management.
* All participants participating in sexual activity that could lead to pregnancy must use an FDA approved method of birth control.
* Participant is not suffering from significant wasting (e.g. body mass index \<21) thought to be related to HIV disease.

Exclusion Criteria:

* Participant has a history of progressive multifocal leukoencephalopathy (PML) or primary central nervous system (CNS) lymphoma.
* Participant is pregnant or breastfeeding.
* Past or current medical problems or findings from medical history, physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks or may impact the quality or interpretation of the data obtained from the study.

Locations (29)

Birmingham, Alabama, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
San Diego, California, United States
San Francisco, California, United States
New Haven, Connecticut, United States
Washington D.C., District of Columbia, United States
Miami, Florida, United States
Weston, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
New York, New York, United States
Cincinnati, Ohio, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Dallas, Texas, United States
Dallas, Texas, United States
Charlottesville, Virginia, United States